Therefore, our data should also raise awareness that, in such applications, drugs targeting BRD9 may have the undesirable side effect of limiting the effectiveness of endogenous host innate antiviral IFN responses, thereby potentially increasing the susceptibility of individuals to some infections. The gene discussed is BRD9; the disease is infection.